-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, D8Np/4AitBY7iVsMePtkk8g+i3Ui+V3g/vqEOajCGbqwGDqYEUAOwjrqJxZ27eeL TgN0ErBHYQMce7lkFZcqZw== 0001116679-05-002812.txt : 20051129 0001116679-05-002812.hdr.sgml : 20051129 20051129153842 ACCESSION NUMBER: 0001116679-05-002812 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20051123 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20051129 DATE AS OF CHANGE: 20051129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROTEIN POLYMER TECHNOLOGIES INC CENTRAL INDEX KEY: 0000858155 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 330311631 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19724 FILM NUMBER: 051231858 BUSINESS ADDRESS: STREET 1: 10655 SORRENTO VALLEY RD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195586064 MAIL ADDRESS: STREET 1: 10655 SORRENTO VALLEY ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 ppt8k.txt ================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2005 PROTEIN POLYMER TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 0-19724 33-0311631 - -------------------------- ----------------------- -------------------------- (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.) 10655 Sorrento Valley Road, San Diego, California 92121 - ----------------------------------------------------------- ------------------ Registrant's telephone number, including area code: (858) 558-6064 -------------- Not Applicable - ------------------------------------------------------------------------------- (Former name or former address, if changed since last report) ================================================================================ ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. On November 23, 2005, Protein Polymer Technologies, Inc. (the "Company") entered into an Asset Purchase Option Agreement (the "Option Agreement"), dated as of the same date, by and between the Company and Surgica Corporation ("Surgica") pursuant to which the Company is granted a one-year option (and a one-year option extension) to acquire substantially all of Surgica's assets in exchange for two million (2,000,000) shares of the Company's Common Stock (the "Shares") and a potential future incentive issuance of additional Company Common Stock (the "Earnout Shares") based on the future sales performance of Surgica's products during the first quarter of 2007. The Shares and the Earnout Shares are sometimes referred to herein individually and collectively as the "Securities". The full text of the Option Agreement is included as Exhibit 10.1 to this Report. The closing of the Option Agreement (the "Option Closing") is subject to certain conditions precedent, but is scheduled to close no later than December 17, 2005. Concurrently with the Option Closing, if at all, and pursuant to the Option Agreement's terms, the Company and Surgica will enter into a License Agreement and Supply and Services Agreement, pursuant to which the Company will acquire exclusive rights to Surgica's technology and products. The Company's obligation to the Option Closing is subject to the execution of a number of other agreements: (i) the consent of AngioDynamics, Inc. for the assignment by Surgica to the Company of all of Surgica's rights and obligations under the Distributor Agreement, dated as of June 28, 2002, by and between Surgica and AngioDynamics, Inc.; (ii) a voting agreement (and proxy) between the Company and Louis R. Matson; (iii) an employment agreement between Surgica and Louis R. Matson to expire no later than December 31, 2007; and (iv) a side letter agreement between the Company and Louis R. Matson pursuant to which Louis R. Matson represents and warrants that, to his actual knowledge, each of the representations and warranties of Surgica set forth in the Option Agreement is true and correct at and as of the date the Option Agreement was executed. The following is a brief summary of the transaction. This summary is qualified in its entirety by reference to the full text of the Option Agreement, which is attached hereto as Exhibit 10.1 to this Report, and any reports, definitive proxy statements or information statements filed subsequent to this Report by the Company under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act in the form filed with the Securities Exchange Commission that relate to the transaction. Asset Purchase Option Agreement -------------------------------- Under the terms of the Option Agreement, the Company will have the right to acquire substantially all of the assets of Surgica for (i) the Shares, and (ii) the Earnout Shares, if any, based on the future sales performance of Surgica's products during the first quarter of 2007. The number of Earnout Shares, if any, will be based in part on the price per share of the Company's Common Stock based on the 90 day prior average price of the Company's Common Stock as of April 1, 2007 (the "Trailing Average Price"). The option will be effective as of the Option Closing and will be exercisable, at the sole discretion of the Company, for a term of up to two (2) years. The Option Closing is subject to a number of conditions precedent, including approval of the Option Agreement by a majority of the holders Surgica's common stock and preferred stock voting as a single class, with the preferred voting on an "as converted" basis. If and when Surgica is given notice of the Company's intent to exercise the option, the exercise of the option itself will be subject to approval by Surgica's stockholders. License Agreement and Supply and Services Agreement --------------------------------------------------- Concurrently with the Option Closing, the Company and Surgica will enter into a License Agreement and Supply and Services Agreement. Under the terms of the License Agreement, the Company will acquire exclusive rights to Surgica's three embolization products, one issued patent, and technical and market know-how in return for (i) the assumption of up to approximately $650,000.00 of certain Surgica liabilities and (ii) a cash payment(s) to Surgica of up to approximately $400,000.00. Under the terms of the Supply and Services Agreement, Surgica will be obligated to provide its goods and services, including further product development, in exchange for (i) operating payments to Surgica and (ii) a royalty of twenty-five percent (25%) of net profits, if any, on revenues generated by the sale of Surgica products. Employment Agreement --------------------- Under the terms of the Option Agreement, one closing condition to the Company's obligation to the Option Closing is that Louis R. Matson and Surgica enter into an Employment Agreement that provides, among other things, that Louis R. Matson (i) retain the title of President of Surgica; (ii) be paid a specified base salary; and (iii) be employed until December 31, 2007, unless terminated prior to such date. It is currently contemplated that this the Employment Agreement will be assumed by the Company or a wholly-owned subsidiary of the Company if and when the Company exercises the option. Voting Agreement and Proxy --------------------------- Under the terms of the Option Agreement, one closing condition to the Company's obligation to the Option Closing is that the Company and Louis R. Matson enter into a Voting Agreement pursuant to which Louis R. Matson agrees to vote all shares of Surgica that he may own (i) in favor of the adoption of the Option Agreement and the grant of the option contemplated thereby; (ii) in favor of adoption of the Asset Purchase Agreement and approval of the acquisition contemplated thereby, but only to the extent that the option is exercised by the Company; (iii) against any proposal for any acquisition transaction, other than the acquisition, between Surgica and any person other than the Company and/or a wholly-owned subsidiary of the Company; and (iv) against any other action or agreement that would result in a breach of any covenant, representation or warranty or any other obligation or agreement of Surgica under the Option Agreement or Asset Purchase Agreement or which would result in any of the conditions to the consummation of the effectiveness of the option under the Option Agreement or the acquisition under the Asset Purchase Agreement not being fulfilled. Concurrently with the execution of the Voting Agreement, and pursuant to the Voting Agreement's terms, Louis R. Matson agrees to deliver to the Company an irrevocable proxy appointing the Company as the sole and exclusive attorney and proxy of Louis R. Matson, with full power of substitution and resubstitution, to vote and exercise all voting and related rights with respect to all shares of Surgica that he may own in accordance with (ii), (iii), and (iv) above. Asset Purchase Agreement ------------------------ Pursuant to the terms of the Option Agreement, upon the Option Closing, the Company will have up to two (2) years to exercise an option to purchase substantially all of the assets of Surgica in exchange for the Shares and the Earnout Shares, if any, by entering into, and causing a to-be-formed, wholly-owned subsidiary of the Company to enter into, a definitive Asset Purchase Agreement with Surgica which will be subject to a number of conditions precedent, including approval by Surgica's stockholders. Pursuant to the terms of the Asset Purchase Agreement, the Securities shall constitute "restricted securities" as that term is defined in Section 144(a)(3) of the Securities Act of 1933, as amended, and shall be restricted as to their resale for a period of at least one hundred eighty (180) days from the date the Asset Purchase Agreement is executed. The Earnout Shares, if any, will be equal to the aggregate amount of (i) the "Common Stock Equivalent A", defined below, for every $1.00 in annualized first quarter revenue for the first (1st) quarter of 2007 derived from the operations to be transferred from Surgica to the Company (the "Annualized First Quarter Revenue") up to, and including, $2,000,000.00 plus (ii) the "Common Stock Equivalent B", defined below, for every $1.00 in Annualized First Quarter Revenue in excess of $2,000,000.00. Common Stock Equivalent A means the number of shares of the Company's Common Stock equal to the quotient of (i) $0.50 divided by (ii) the Trailing Average Price. Common Stock Equivalent B means the number of shares of the Company's Common Stock equal to the quotient of (i) $1.00 divided by (ii) the Trailing Average Price. The Earnout Shares will be issued, if at all, only if the average sales per quarter from the operations to be transferred from Surgica to the Company for the first (1st) and second (2nd) quarters of 2007 are equal to or greater than a predetermined set amount. Each of the Option Agreement, License Agreement, Supply and Services Agreement and Asset Purchase Agreement contain representations and warranties by the Company and Surgica customary for transactions of this type. On November 28, 2005, the Company issued a press release, in the form attached to this Current Report on Form 8-K as Exhibit 99.1, that describes the above-mentioned arrangements. ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (c) Exhibits. 10.1 Asset Purchase Option Agreement, dated as of November 23, 2005, by and between Protein Polymer Technologies, Inc. and Surgica Corporation. 99.1 Press Release of Protein Polymer Technologies, Inc. dated as of November 28, 2005. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROTEIN POLYMER TECHNOLOGIES, INC., a Delaware corporation Date: November 29, 2005 By: /s/ J. Thomas Parmeter ---------------------- J. Thomas Parmeter Chairman of the Board EXHIBIT INDEX Exhibit No. Description - ----------- ----------- 10.1 Asset Purchase Option Agreement, dated as of November 23, 2005, by and between Protein Polymer Technologies, Inc. and Surgica Corporation. 99.1 Press Release of Protein Polymer Technologies, Inc. dated as of November 28, 2005. EX-10 2 ex10-1.txt EX. 10.1 Exhibit 10.1 ================================================================================ ASSET PURCHASE OPTION AGREEMENT BY AND BETWEEN PROTEIN POLYMER TECHNOLOGIES, INC. and SURGICA CORPORATION November 23, 2005 ================================================================================ ASSET PURCHASE OPTION AGREEMENT THIS ASSET PURCHASE OPTION AGREEMENT (this "Agreement") is made and entered into as of November 23, 2005 by and between Surgica Corporation, a Delaware corporation (the "Company") and Protein Polymer Technologies, Inc., a Delaware corporation (the "Optionee"). Unless otherwise defined herein, all capitalized terms used herein shall have the respective meanings ascribed thereto in the Purchase Agreement (defined below). R E C I T A L S WHEREAS, the Company and the Optionee propose to enter into that certain License Agreement and that certain Supply and Services Agreement, attached hereto as Exhibit A and Exhibit B, respectively (collectively, the "License Agreement"), pursuant to which the Company, among other things, would license to Optionee certain intellectual property (including patent and patent applications), as well as marketing and distribution rights; WHEREAS, in order to induce the Optionee to enter into the License Agreement and to advance funds to the Company, pursuant to this Agreement and subject to the terms herein, the Optionee shall have the right to purchase from the Company substantially all of the assets of the Company now existing or hereafter acquired through the date of the exercise of the Option (defined below) (the "Assets") for the purchase price described in Section 1.4 of this Agreement. NOW, THEREFORE, in consideration of the premises and mutual covenants and agreements herein set forth and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, each of the parties hereto (individually, a "Party", collectively, the "Parties") hereby agree as follows: ARTICLE I OPTION TO PURCHASE Section 1.1. Option to Purchase Assets. --------------------------------------- Subject to the satisfaction or waiver of the conditions set forth in Article V hereof, the Company hereby grants to Optionee the option to purchase substantially all of the Assets (the "Option") during the Option Period (as defined in Section 1.2 of this Agreement), as the same may be extended pursuant to the terms hereof, or such later date as the Parties shall mutually agree upon. The date on which the Option becomes effective is referred to herein as the "Option Effective Date." -1- Section 1.2. The Option Period. ------------------------------- The "Option Period" shall commence on the date hereof and extend until One (1) year from the Effective Date, provided that, upon written notice from Optionee to the Company not more than 60 days and not less than 30 days prior to such date, the Option Period may be extended until Two (2) years from the Effective Date, in the sole and absolute discretion of Optionee. Section 1.3. Exercise of Option. -------------------------------- (a) During the Option Period, Optionee may exercise the Option only upon written notice (the "Option Notice") to the Company, in accordance with Section 7.7 herein. (b) Within 10 days after the Optionee delivers the Option Notice, the Optionee, Optionee's wholly-owned subsidiary and the Company, must enter into a definitive asset purchase agreement in substantially the form attached hereto as Exhibit C (the "Purchase Agreement"). Section 1.4. Option Payment. ---------------------------- The consideration which shall be paid by Optionee to the Company for the Assets shall be equal to that set forth in Section 2.6 of the Purchase Agreement. Section 1.5. Option Closing. ---------------------------- The Option shall become effective (the "Option Closing") on the Option Effective Date, which shall be one Business Day after satisfaction or waiver of all the conditions set forth in Article V hereof, but in no event later than December 17, 2005. At the Option Closing, the parties shall enter into the License Agreement and Supply and Services Agreement and shall execute and deliver such other instruments and documents contemplated by Article V hereof. ARTICLE II REPRESENTATIONS AND WARRANTIES OF THE COMPANY The Company represents and warrants to the Optionee for its benefit that the statements contained in this Article II are true and correct, subject to such exceptions as are specifically disclosed in writing in the Disclosure Schedule provided by the Company to the Optionee (the "Disclosure Schedule"). Section 2.1. Organization, Qualification and Corporate Power. ------------------------------------------------------------- The Company is a corporation duly organized, validly existing and in corporate good standing under the laws of the State of Delaware. The Company is duly qualified to conduct business and is in corporate good standing under the -2- laws of each jurisdiction in which the nature of its businesses or the ownership or leasing of its properties requires such qualification, except where the failure to be so qualified or in good standing would not have a Material Adverse Effect on the Company. The Company has the corporate power and authority to carry on the businesses in which it is engaged and to own and use the properties owned and used by it. The Company has furnished or made available to the Optionee true and complete copies of its Certificate of Incorporation and Bylaws, each as amended and/or restated and as in effect on the date hereof (hereinafter the "Charter" and "Bylaws," respectively). The Company is not in default under or in violation of any provision of its Charter or Bylaws, each as amended to date. Section 2.2. Representations and Warranties in Purchase Agreement. ------------------------------------------------------------------ The representations and warranties regarding the Company set forth in Article III of the Purchase Agreement are true and correct as of the date hereof. Section 2.3. Authorization of Transaction. ------------------------------------------ Subject to the Requisite Stockholder Approval (as defined below) of this Agreement, the Company has the corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder. The execution and delivery of this Agreement and, subject to the adoption of this Agreement, the proper notice or waiver thereof to the Company's preferred stockholders as provided in the Charter and Bylaws of the Company and the approval of the transaction by a majority of the votes represented by the outstanding shares of stock entitled to vote on this Agreement, which is a majority of the Company's common stock and preferred stock voting as a single class, with the preferred voting on an "as converted" basis, voting in accordance with the corporate laws of the State of Delaware and the Charter and Bylaws of the Company (the "Requisite Stockholder Approval"), the performance by the Company of this Agreement and the consummation by the Company of the transactions contemplated hereby have been duly and validly authorized by all necessary corporate action on the part of the Company. This Agreement has been duly and validly executed and delivered by the Company and, assuming the due authorization, execution and delivery by the Optionee, constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws affecting the enforcement of creditors' rights generally, and except that the availability of equitable remedies, including specific performance, is subject to the discretion of the court before which any proceeding therefor may be brought. Section 2.4. Noncontravention. ------------------------------ Subject to receipt of the Requisite Stockholder Approval and the consent of AngioDynamics, Inc., substantially in the form as set forth on Exhibit D, attached hereto, except as set forth on Schedule 2.4, attached hereto, neither the execution and delivery of this Agreement by the Company, nor the consummation by the Company of the transactions contemplated hereby, will: (a) conflict with or violate any provision of the Charter or Bylaws of the Company; (b) require on the part of the Company any filing with, or any permit, authorization, consent or approval of, any Governmental Body; (c) conflict with, -3- result in a breach of, constitute (with or without due notice or lapse of time or both) a default under, result in the acceleration of, create in any party the right to accelerate, terminate, modify or cancel, or require any notice, consent or waiver under, any contract, lease, sublease, license, sublicense, franchise, permit, indenture, agreement or mortgage for borrowed money, instrument of indebtedness, Lien or other arrangement to which the Company is a party or by which the Company is bound or to which any of its Assets is subject; (d) result in the imposition of any Lien upon any Assets of the Company; or (e) violate any order, writ, injunction, decree, statute, rule or regulation applicable to the Company, any of its properties or Assets. Section 2.5. Subsidiaries. -------------------------- The Company does not have any direct or indirect subsidiaries or any other equity interest in any other firm, corporation, partnership, joint venture, association or other business organization. Section 2.6. Absence of Certain Changes. ---------------------------------------- Since June 30, 2005, the Company has conducted its business in the Ordinary Course of Business and there has not occurred any change, event or condition (whether or not covered by insurance) that has resulted in, or might reasonably be expected to result in any material adverse change in the Assets, business, financial condition or results of operations of the Company. Section 2.7. Powers of Attorney. -------------------------------- There are no outstanding powers of attorney executed on behalf of the Company. Section 2.8. Fees. ------------------ Except as disclosed in Schedule 2.8, the Company has no liability or obligation to pay any fees or commissions to any broker, investment banking firm, finder or agent with respect to the transactions contemplated by this Agreement. Section 2.9. Books and Records. ------------------------------- The minute books and other similar records of the Company contain true and complete records of all material actions taken at any meetings of the stockholders of the Company, Board of Directors or any committee thereof and of all written consents executed in lieu of the holding of any such meeting. Section 2.10. Company Action. ----------------------------- The Board of Directors of the Company, at a meeting duly called and held, has by the unanimous vote of all directors (i) determined that the transaction contemplated herein is fair and in the best interests of the Company and its stockholders, (ii) adopted this Agreement in accordance with the provisions of the corporate laws of the State of Delaware, and (iii) directed that this Agreement be submitted to the stockholders of the Company for their -4- adoption and approval and resolved to recommend that the stockholders of the Company vote in favor of the adoption of this Agreement. Section 2.11. Disclosure. ------------------------- No representation or warranty by the Company contained in this Agreement, and no statement contained in the Disclosure Schedule or any other document, certificate or other instrument delivered to or to be delivered by or on behalf of the Company pursuant to this Agreement, contains any untrue statement of a material fact or omits to state any material fact necessary, in light of the circumstances under which it was made, in order to make the statements herein not misleading. ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE OPTIONEE The Optionee represents and warrants to the Company as follows: Section 3.1. Organization. -------------------------- The Optionee is a corporation duly organized, validly existing and in good standing under the laws of the state of Delaware. The Optionee is duly qualified to conduct business and is in corporate good standing under the laws of each jurisdiction in which the nature of its businesses or the ownership or leasing of its properties requires such qualification, except where the failure to be so qualified or in good standing would not have a Material Adverse Effect on it. Section 3.2. Authorization of Transaction. ------------------------------------------ The Optionee has all corporate requisite power and authority to execute and deliver this Agreement and to perform its obligations hereunder and thereunder. The execution and delivery of this Agreement and the performance of this Agreement and the consummation of the transactions contemplated hereby and thereby by the Optionee have been duly and validly authorized by all necessary corporate action on the part of the Optionee. This Agreement has been duly and validly executed and delivered by the Optionee and, assuming the due authorization, execution and delivery by the Company, constitutes a valid and binding obligation of the Optionee, enforceable against it in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency or other similar laws affecting the enforcement of creditors' rights generally, and except that the availability of equitable remedies, including specific performance, is subject to the discretion of the court before which any proceeding therefor may be brought. Section 3.3. Noncontravention. ------------------------------ Neither the execution and delivery of this Agreement, nor the consummation by the Optionee of the transactions contemplated hereby, will (a) conflict or violate any provision of the Certificate of Incorporation or Bylaws -5- of the Optionee, (b) conflict with, result in breach of, constitute (with or without due notice or lapse of time or both) a default under, result in the acceleration of, create in any party any right to accelerate, terminate, modify or cancel, or require any notice, consent or waiver under, any contract, lease, sublease, license, sublicense, franchise, permit, indenture, agreement or mortgage for borrowed money, instrument of indebtedness, security interest or other arrangement to which the Optionee is a party or by which either is bound or to which any of their assets are subject, or (c) violate any order, writ, injunction, decree, statute, rule or regulation applicable to the Optionee or any of its properties or assets. Section 3.4. Company Action. ---------------------------- The Board of Directors of the Optionee, at a meeting duly called and held, have (i) determined that the transaction contemplated herein is fair and in the best interests of the Optionee and each of its stockholders, and (ii) adopted this Agreement in accordance with the provisions of the Delaware General Corporation Law. Section 3.5. Brokers' Fees. --------------------------- The Optionee has no liability or obligation to pay any fees or commissions to any broker, finder or agent with respect to the transactions contemplated by this Agreement. Section 3.6. Financial Reports and SEC Documents. ------------------------------------------------- The Optionee's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2004, as amended by Form 10-KSB/A filed on May 18, 2005, and all other reports, definitive proxy statements or information statements filed or to be filed by it subsequent to December 31, 2004 under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act in the form filed or to be filed (collectively, "SEC Documents") with the SEC, as of the date filed or to be filed, (A) complied or will comply in all material respects as to form with the applicable requirements under the Exchange Act and (B) as of the time filed, or to be filed, did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each of the balance sheets contained in or incorporated by reference into any such SEC Document (including the related notes and schedules thereto) fairly presents, or will fairly present, the financial position of Optionee and its subsidiaries, if any, as of its date, and each of the statements of income and changes in shareholders' equity and cash flows or equivalent statements in such SEC Documents (including any related notes and schedules thereto) fairly presents, or will fairly present, the results of operations, changes in shareholders' equity and changes in cash flows, as the case may be, of Optionee and its subsidiaries, if any, for the periods to which they relate, in each case in accordance with U.S. GAAP consistently applied during the periods involved, except in each case as may be noted therein, subject to the absence of footnotes and to normal year-end adjustments in the case of unaudited statements. -6- ARTICLE IV COVENANTS BY THE OPTIONEE AND THE COMPANY The Optionee and the Company covenant as follows: Section 4.1. Satisfaction of Conditions. ---------------------------------------- Each of the Parties shall use its commercially reasonable efforts to take all actions and to do all things necessary, proper or advisable to satisfy the conditions set forth in Article V of this Agreement. Section 4.2. Notices and Consents. ---------------------------------- Each of the Optionee and the Company shall use their commercially reasonable efforts to obtain, at its expense, all such waivers, permits, consents, approvals or other authorizations from third parties and Governmental Bodies, and to effect all such registrations, filings and notices with or to third parties and Governmental Bodies, as may be required by or with respect to the Optionee or the Company, respectively, in connection with the transactions contemplated by this Agreement. Section 4.3. Operation of Business. ----------------------------------- Except as contemplated by this Agreement, during the period from the date of this Agreement up until the Closing Date (as defined in the Purchase Agreement), the Company shall conduct its operations in the Ordinary Course of Business and in compliance with all applicable laws and regulations and, to the extent consistent therewith, use all reasonable efforts to preserve intact its current business organization, keep its physical Assets in good working condition, keep available the services of its current officers and employees and preserve its relationships with customers, suppliers and others having business dealings with it to the end that its goodwill and ongoing business shall not be impaired in any material respect. Without limiting the generality of the foregoing, prior to the Closing Date, the Company shall not, without the written consent of the Optionee: (a) issue, sell, deliver or agree or commit to issue, sell or deliver (whether through the issuance or granting of options, warrants, commitments, subscriptions, rights to purchase or otherwise) or authorize the issuance, sale or delivery of, or redeem or repurchase, any stock of any class or any other securities or any rights, warrants or options to acquire any such stock or other securities (except pursuant to the conversion or exercise of convertible securities, options or warrants outstanding on the date hereof), or amend any of the terms of any such convertible securities, options or warrants; (b) split, combine or reclassify any shares of its capital stock; declare, set aside or pay any dividend, special bonus or other distribution (whether in cash, stock or property or any combination thereof) in respect of its capital stock; -7- (c) create, incur or assume any debt not currently outstanding (including obligations in respect of capital leases); assume, guarantee, endorse or otherwise become liable or responsible (whether directly, contingently or otherwise) for the obligations of any other person or entity; or make any loans, advances or capital contributions to, or investments in, or increase the amount of any existing loan to any other person or entity; (d) enter into, adopt or amend any Plans or any employment or severance agreement or arrangement or increase in any manner the compensation or fringe benefits of, or modify the employment terms of, its directors, officers or employees, generally or individually, or pay any benefit not required by the terms in effect on the date hereof of any existing Plan; (e) acquire, sell, transfer, lease, sublease, license, abandon, encumber, transfer or otherwise dispose of any properties or assets, real, personal or mixed (including leasehold interests and intangible property) related to the Operations, except in the Ordinary Course of Business (f) amend and/or restate its Charter or Bylaws; (g) change in any material respect its accounting methods, principles or practices, or make any change in depreciation or amortization policies or lives adopted by it except insofar as may be required by a generally applicable change in GAAP or as required by Optionee; (h) discharge or satisfy any Lien or pay any obligation or liability other than in the Ordinary Course of Business; (i) settle, compromise, materially modify or amend, waive, terminate, cancel, release or assign any rights or Claims concerning, affecting or relating to any Contract relating to the Operations (including, without limitation, any Assigned Agreement), or otherwise relating to the Operations; (j) mortgage or pledge any of its property or Assets or subject any such Assets to any Lien; (k) sell, assign, license, grant or transfer any rights under, or enter into any settlement regarding the breach or infringement of, any Intellectual Property, or modify any existing rights with respect thereto; (l) enter into, amend, terminate, take or omit to take any action that would constitute a violation of or default under, or waive, release or assign any rights under, any contract or agreement; (m) enter into, amend, modify or consent to the termination of any Assigned Agreement; -8- (n) make or commit to make any capital expenditure in excess of Five Thousand Dollars ($5,000) per item; (o) take any action or fail to take any action permitted by this Agreement with the knowledge that such action or failure to take action would result in (i) any of the representations and warranties of the Company set forth in this Agreement or the Purchase Agreement becoming untrue or (ii) any of the conditions to the transaction set forth in Article V, not being satisfied; (p) make any material charitable contribution; (q) engage or terminate any consultant; (r) enter into, materially amend or (except in conjunction with the completion of the term thereof) terminate any Contract or transaction with any director or officer, stockholder or Affiliate of Seller (or with any relative, beneficiary, spouse or Affiliate of such Person) relating to the Operations; (s) terminate, discontinue, close or dispose of any facility or other business operation, or lay off any employees or implement any early retirement, separation or program providing early retirement window benefits or announce or plan any such action or program for the future; (t) allow any Permit that was issued or relates to the Operations to lapse or terminate or fail to renew any insurance policy or Permit that is scheduled to terminate or expire within forty five (45) calendar days of the Effective Date, except to the extent that such failure would not be reasonably expected to cause a Material Adverse Effect on the ability of the Company to own and operate the Operations as now conducted; (u) enter into any contract, other than in the Ordinary Course of Business and as provided to the Optionee, or any amendment or termination of, or default under, any contract that is or was material to the Operations or Seller's rights thereunder; (v) commence any litigation other than (i) for the routine collection of bills or (ii) in such cases where the Company in good faith determines that failure to commence suit would result in the material impairment of a valuable aspect of the Company's business, provided that Company consults with the Optionee prior to the filing of such a suit; (w) make or change any material election in respect of Taxes, adopt or change any accounting method in respect of Taxes, file any material return or any amendment to a material return, enter into any closing agreement, settle any claim or assessment in respect of Taxes (except settlements effected solely through payment of immaterial sums of money), or consent to any extension or waiver of the limitation period applicable to any claim or assessment in respect of Taxes; -9- (x) write down or write up (or fail to write down or write up in accordance with U.S. GAAP consistent with past practice) the value of any receivables or revalue any of the Company's assets other than in the Ordinary Course of Business and in accordance with U.S. GAAP; (y) issue any purchase orders or otherwise agreed to make any purchases involving exchanges in value in excess of Two Thousand Five Hundred Dollars and Zero Cents ($2,500.00) individually or Five Thousand Dollars and Zero Cents ($5,000.00) in the aggregate, except in the Ordinary Course of Business; (z) merge with, enter into a consolidation with or acquire an interest of 5% or more in any Person or acquire a substantial portion of the assets or business of any Person or any division or line of business thereof engaged in a business relating to the Operations, or otherwise acquire any material assets relating to the Operations except in the Ordinary Course of Business; (aa) (i) grant, announce, or make any change in the rate of compensation, wages, salaries, commission, bonuses, incentives, pensions or other direct or indirect remuneration or benefits payable, or pay or agree or orally promised to pay, conditionally or otherwise, any bonus, incentive, retention or other compensation, retirement, welfare, fringe or severance benefit or vacation pay, to or in respect of any director, officer, employee, distributor, contractor, or agent of the Company relating to or involved in the Operations, including any increase or change pursuant to any Plan or (ii) enter into, establish, increase or promise to increase, amend or terminate any benefits under any Plan or any employment or severance agreement or commitment or collective bargaining agreement with any employee or contractor of the Company relating to or involved in the Operations, in either case except as required by Law or any collective bargaining agreement, such exceptions being disclosed in the Disclosure Schedules; (bb) fail to pay any creditor any material amount owed to such creditor when due; (cc) change in any manner the character or scope of the Operations; or (dd) agree, whether in writing or otherwise, to take any action described in this Section 4.3 or grant any options to purchase, rights of first refusal, rights of first offer or any other similar rights or commitments with respect to any of the actions specified in this Section 4.3, except as expressly contemplated by this Agreement. Section 4.4. Full Access. ------------------------- The Company shall permit representatives of the Optionee to have full access (upon reasonable notice and at all reasonable times, and in a manner so as not to interfere with the normal business operations of the Company) to all -10- premises, properties, financial and accounting records, contracts, other records and documents, and personnel, of or pertaining to the Company, subject to compliance with applicable confidentiality obligations of the Company. Section 4.5. Notice of Breaches. -------------------------------- The Company shall promptly deliver to the Optionee written notice of any event or development of which the Company is aware and that would (a) render any statement, representation or warranty of the Company in this Agreement (including the Disclosure Schedule) inaccurate or incomplete in any material respect, or (b) constitute or result in a breach by the Company of, or a failure by the Company to comply with, any agreement or covenant in this Agreement applicable to such Party. The Optionee shall promptly deliver to the Company written notice of any event or development of which the Optionee is aware that would (i) render any statement, representation or warranty of the Optionee in this Agreement inaccurate or incomplete in any material respect, or (ii) constitute or result in a breach by the Optionee of, or a failure by the Optionee to comply with, any agreement or covenant in this Agreement applicable to such Party. No such disclosure shall be deemed to avoid or cure any such misrepresentation or breach. Section 4.6. Exclusivity. ------------------------- The Company agrees that from the date of execution of this Agreement until the earlier of (a) the Closing Date or (b) termination of this Agreement in accordance with Article VI hereof, the Company shall not, and the Company shall use its best efforts to cause each of its officers, directors, employees, representatives and agents not to, directly or indirectly, (a) solicit, initiate, engage or participate in or knowingly encourage discussions or negotiations with any person or entity (other than the Optionee) concerning any merger, consolidation, sale of assets, tender offer, recapitalization, accumulation of stock, proxy solicitation or other business combination involving the Company or any division of the Company, (b) solicit, initiate, entertain or encourage any proposal or offer related to such an acquisition, (c) provide any non-public information concerning the business, properties or Assets of the Company to any person or entity (other than the Optionee) or (d) enter into any understanding, letter of intent or agreement, whether binding or non-binding, in connection with the foregoing. The Company shall immediately notify the Optionee of, and shall disclose to the Optionee all details of, any inquiries, discussions or negotiations of the nature described in the first sentence of this Section 4.6. The term "indirectly" shall include, but not be limited to, through Company representatives. Section 4.7. Reasonable Commercial Efforts and Further Assurances. ------------------------------------------------------------------ Each of the Parties shall use reasonable commercial efforts to effectuate the transactions contemplated hereby and to fill and cause to be fulfilled the conditions to closing under this Agreement. Each Party, at the reasonable request of another Party, shall execute and deliver such other instruments and do and perform such other acts and things as may be necessary or desirable for effecting completely the consummation of this Agreement and the transactions contemplated hereby. -11- Section 4.8. Funding of Business Plan. -------------------------------------- If the Closing occurs prior to June 30, 2007, absent a Material Adverse Effect, as determined by and in the sole discretion of Optionee, Optionee shall provide support, as more fully described in Schedule 4.8, to the Operations to be transferred from Seller to Optionee as provided herein in order to, in the reasonable judgment of Optionee, enable the Minimum Revenue Trigger to be met. It is currently anticipated that such support, if any, will be reflected in the approval budgets for the Operations to be transferred from Seller to Optionee as further described in the Supply and Services Agreement. ARTICLE V CONDITIONS TO CONSUMMATION OF TRANSACTION Section 5.1. Conditions to Each Party's Obligations. ---------------------------------------------------- The respective obligations of each Party to the Option Closing hereunder are subject to the following conditions: (a) The Company shall have received the Requisite Stockholder Approval from the stockholders of the Company. (b) Any required notice to the Company's preferred stockholders shall have been given or waived; and (c) Subject to the Requisite Stockholder Approval, Company and the Optionee shall have entered into the License Agreement. Section 5.2. Conditions to Obligations of the Optionee. ------------------------------------------------------- The obligation of the Optionee to the Option Closing hereunder is subject to the satisfaction of the following additional conditions: (a) the Company shall have performed or complied with in all material respects its agreements and covenants required to be performed or complied with under this Agreement as of or prior to the Option Closing; (b) the representations and warranties of the Company set forth in Article II shall be true and correct as of the date hereof, and shall be true and correct as of the Option Closing, except for representations and warranties made as of a specific date, which shall be true and correct as of such date; (c) the Company shall have delivered to the Optionee a certificate (without qualification as to knowledge or materiality or otherwise) to the effect that each of the conditions specified in clauses (a) and (b) of this Section 5.2 is satisfied in all respects; -12- (d) The Company shall have received the consent of AngioDynamics, Inc., substantially in the form of Exhibit D, attached hereto, to assign the Company's rights and obligations under that certain Distributor Agreement, dated as of June 28, 2002, between the Company and AngioDynamics, Inc. (e) Louis R. Matson shall have entered into a Voting Agreement, substantially in the form attached hereto as Exhibit E; and (f) Louis R. Matson and the Company shall have entered into an Employment Agreement substantially in the form set forth on Exhibit F hereto; and (g) Louis R. Matson and the Optionee shall have entered into a Side Letter Agreement substantially in the form set forth on Exhibit G hereto. Section 5.3. Conditions to Obligations of the Company. ------------------------------------------------------ The obligation of the Company to consummate the Option Closing hereunder is subject to the satisfaction of the following additional conditions: (a) The Optionee shall have performed or complied with in all material respects its agreements and covenants required to be performed or complied with under this Agreement as of or prior to the Option Closing; (b) the representations and warranties of the Optionee set forth in Article III shall be true and correct as of the date hereof, and shall be true and correct as of the Option Closing, except for representations and warranties made as of a specific date, which shall be true and correct as of such date; and (c) the Optionee shall have delivered to the Company a certificate (without qualification as to knowledge or materiality or otherwise) to the effect that each of the conditions specified in clause (a) and (b) of this Section 5.3 is satisfied in all respects. ARTICLE VI TERMINATION Section 6.1. Termination of Agreement. -------------------------------------- The Parties may terminate this Agreement prior to the Closing Date as provided below: (a) the Parties may terminate this Agreement by mutual written consent; (b) any Party may terminate this Agreement by giving written notice to the other Parties upon the entry of any permanent injunction or other order of a court or other competent authority preventing the consummation of the transaction that has become final and nonappealable; -13- (c) The Optionee may terminate this Agreement if any of the conditions set forth in Section 5.1 or 5.2 is not satisfied on or prior to December 17, 2005 and the Optionee is not then in breach of this Agreement; (d) the Company may terminate this Agreement if any of the conditions set forth in Section 5.1 or 5.3 are not satisfied on or prior to December 17, 2005 and the Company is not then in breach of this Agreement; and (e) the Optionee may terminate this Agreement for any reason prior to the Closing Date. Section 6.2. Effect of Termination. ----------------------------------- If any Party terminates this Agreement pursuant to Section 6.1, all obligations of the Parties shall terminate without any liability of any Party to any other Party. Notwithstanding the foregoing, the following obligations shall survive termination of this Agreement: (i) liability of any Party for breaches of this Agreement; (ii) confidentiality, as provided in Section 7.1; and (iii) each Party's obligation to bear its own fees and expenses incurred in connection with the preparation and negotiation of this Agreement and the transactions contemplated herein as provided in Section 7.11. Section 6.3. Amendment. ----------------------- The Parties may cause this Agreement to be amended at any time by execution of an instrument in writing signed on behalf of each of the Parties. Section 6.4. Extension; Waiver. ------------------------------- At any time prior to the Closing Date, any Party may, to the extent legally allowed (i) extend the time for the performance of any of the obligations or other acts of the other Parties; (ii) waive any inaccuracies in the representations and warranties made to such Party contained herein or in any document delivered pursuant hereto and (iii) waive compliance with any of the agreements or conditions for the benefit of such Party contained herein. Any agreement on the part of a Party to any such extension or waiver shall be valid only if set forth in an instrument in writing signed on behalf of such Party. ARTICLE VII MISCELLANEOUS Section 7.1. Press Releases and Announcements. ---------------------------------------------- No Party shall issue any press release or make any public disclosure relating to the subject matter of this Agreement without the prior approval of the other Parties; provided, however, that any Party may make any public disclosure it believes in good faith is required by law or regulation (in which case the disclosing Party shall advise the other Parties and provide them with -14- a copy of the proposed disclosure prior to making the disclosure). Notwithstanding the foregoing, the Parties acknowledge that Optionee is a reporting company under the Securities Exchange Act of 1934, as amended, and will be required to publicly disclose this Agreement and the transactions contemplated hereby in the form of press releases, Current Reports on Form 8-K and such other means as Optionee determines. Section 7.2. No Third Party Beneficiaries. ------------------------------------------ This Agreement shall not confer any rights or remedies upon any person other than the Parties and their respective successors and permitted assigns. Section 7.3. Entire Agreement. ------------------------------ This Agreement, the Disclosure Schedule, the Schedules, the documents and instruments and other agreements among the Parties referred to herein constitute the entire agreement among the Parties and supersedes any prior understandings, agreements or representations by or among the Parties, written or oral, with respect to the subject matter hereof. Section 7.4. Succession and Assignment. --------------------------------------- This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns. No Party may assign either this Agreement or any of its rights, interests, or obligations hereunder without the prior written approval of the other Parties, provided however, that Optionee may assign some or all of its rights hereunder to a wholly owned subsidiary. Section 7.5. Counterparts. -------------------------- This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Section 7.6. Headings. ---------------------- The section headings contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement. Section 7.7. Notices. --------------------- All notices, requests, demands, claims, and other communications hereunder shall be in writing. Any notice, request, demand, claim, or other communication hereunder shall be deemed duly delivered two business days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one business day after it is sent via a reputable nationwide overnight courier service or sent via facsimile (with acknowledgment of complete transmission) with a confirmation copy by registered or certified mail, in each case to the intended recipient as set forth in the Purchase Agreement. -15- Any Party may give any notice, request, demand, claim, or other communication hereunder using any other means (including personal delivery, expedited courier, messenger service, telecopy, telex, ordinary mail, or electronic mail), but no such notice, request, demand, claim, or other communication shall be deemed to have been duly given unless and until it actually is received by the Party for whom it is intended. Any Party may change the address to which notices, requests, demands, claims, and other communications hereunder are to be delivered by giving the other Parties notice in the manner herein set forth. Section 7.8. Governing Law. --------------------------- This Agreement shall be governed by and construed in accordance with the internal laws (and not the law of conflicts) of the State of California. Section 7.9. Amendments and Waivers. ------------------------------------ The Parties may mutually amend any provision of this Agreement at any time prior to Closing Date. No amendment of any provision of this Agreement shall be valid unless the same shall be in writing and signed by all of the Parties. No waiver by any Party of any default, misrepresentation or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent default, misrepresentation, breach of such warranty or covenant. Section 7.10. Severability. --------------------------- Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision hereof is invalid or unenforceable, the Parties agree that the court making the determination of invalidity or unenforceability shall have the power to reduce the scope, duration, or area of the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be enforceable as so modified after the expiration of the time within which the judgment may be appealed, provided that this Agreement shall not then substantially deprive either Party of the bargained-for performance of the other Party. Section 7.11. Expenses. ----------------------- All fees and expenses (including all legal and accounting fees and expenses and all other expenses) incurred by Optionee in connection with this Agreement and the transactions contemplated hereby shall be paid by Optionee whether or not the transaction is consummated. All transaction costs incurred by the Company in connection with this Agreement and the transactions contemplated hereby shall be paid by the Company whether or not the transaction is consummated. -16- Section 7.12. Other Remedies. ----------------------------- Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with, and not exclusive of, any other remedy conferred hereby or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. Section 7.13. Construction. --------------------------- The Parties agree that they have been represented by counsel during the negotiation, preparation and execution of this Agreement and, therefore, waive the application of any law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the Party drafting such agreement or document. Any reference to any federal, state, local, or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. Section 7.14. Incorporation of Schedules and Disclosure Schedule. ----------------------------------------------------------------- The Exhibits, Schedules and Disclosure Schedule identified in this Agreement are incorporated herein by reference and made a part hereof. [Signature page to follow] -17- EXECUTION COPY IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written. SURGICA CORPORATION By: /s/ Louis R. Matson --------------------------------- Name: Louis R. Matson Title: President and Chief Executive Officer PROTEIN POLYMER TECHNOLOGIES, INC. By: /s/ William N. Plamondon, III --------------------------------- Name: William N. Plamondon, III Title: Chief Executive Officer [Signature Page to the Asset Purchase Option Agreement] EX-99 3 ex99-1.txt EX. 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Protein Polymer Technologies and Surgica Sign Option Agreement to Acquire all of Surgica's Assets Agreement Accelerates Protein Polymer Technologies' Commercial Entry San Diego, CA - November 28, 2005 - Protein Polymer Technologies, Inc. (OTC Bulletin Board: PPTI.OB), a biotechnology device company that is a pioneer in protein design and synthesis and Surgica Corporation today announced that they have signed an Asset Purchase Option Agreement which, if the option is exercised, would result in the acquisition of all of Surgica's assets by a wholly-owned subsidiary of PPTI in exchange for PPTI common stock. The option will become effective no later than December 17, 2005, subject to the satisfaction of certain conditions, and upon the effective date, PPTI and Surgica will enter into a License Agreement under which PPTI will acquire exclusive rights to Surgica's technology and products. Currently, Surgica has three Food and Drug Administration (FDA) cleared polyvinyl alcohol (PVA) based embolization products - PVA Plus(TM), MicroStat(TM) and MaxiStat(TM), with additional products in development. Surgica operates a FDA-registered facility for manufacture of these medical devices. "This agreement, together with the license and related agreements, represents a significant milestone in our strategic plan to add shareholder value by bolstering our product portfolio and pipeline with innovative therapies that speed our entry into commercialization," said William N. Plamondon III, Chief Executive Officer of Protein Polymer Technologies. "Surgica's embolization products provide an important minimally invasive treatment option for patients and will allow us to enter the growing embolization market." Transaction Summary Under the terms of the Option Agreement, PPTI will acquire a two-year option to purchase substantially all of Surgica's assets for an initial common stock grant of 2 million shares and a potential future incentive issuance of additional common shares based on future sales performance of Surgica's products. Any securities offered or issued in connection with the purchase of Surgica's assets have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration under such Act or an applicable exemption from such registration requirements. Under the terms of the License Agreement, PPTI will acquire the rights to the three embolization products, one issued patent, and technical and market know-how in return for the assumption of up to approximately $650,000 of certain Surgica liabilities, cash payments of up to approximately $400,000 against certain other Surgica liabilities and a royalty to Surgica of 25 percent of net profits on revenues generated by the sale of the Surgica products. A related Supply and Services Agreement provides for the manufacture of product by Surgica and the provision of services to PPTI, including further product development, in exchange for operating payments to Surgica. The transaction was structured to enable both companies to begin working together as quickly as possible in order to maximize sales growth for the licensed products. When, and if, the Asset Purchase Option is exercised by PPTI, Surgica would then operate as a division of PPTI and it is contemplated that Louis R. Matson, Founder and Chief Executive Officer of Surgica, would assume the role of division president, reporting to Mr. Plamondon. Until such time, Surgica will continue to operate as an independent company with Mr. Matson continuing in his current positions. Key Product Highlights Surgica's patented PVA foam embolization products are manufactured according to a proprietary process, and include both spherical and standard particle forms. Advancing standard PVA technology that has been safely used in humans for over 30-years, Surgica's products have fluid suspension properties intended to maximize product performance. Currently, Surgica's products are cleared for use in endovascular management of arteriovenous malformations (AVMs) and neoplastic lesions when presurgical devascularization is desirable. o PVA Plus(TM) - is used to embolize smaller blood vessels o MaxiStat(TM) - is used to embolize medium blood vessels o MicroStat(TM) - is used to embolize tumors Surgica is also developing an additional product, Blocker(TM) that will be used to embolize larger blood vessels. Beyond Surgica's current indication for use, upon completion of the transaction, PPTI intends to submit a new 510(k) application to the FDA to expand labeled indications for Surgica's products to include treatment of uterine fibroids, liver cancer and certain other applications. PPTI and Surgica also intend to develop drug delivery applications based on the Surgica technology platform. Market Potential Primarily used by interventional radiologists, embolization products are used to treat a variety of medical conditions by blocking blood flow to tissues, damaged blood vessels, vascular malformations and tumors including uterine fibroids. One of the most rapidly growing areas for embolization is the minimally invasive treatment of uterine fibroids. Approximately 70 percent of the projected 275,000 hysterectomies performed to treat uterine fibroids in 2005 would benefit from this procedure. The Company estimates a conservative annual market potential for uterine fibroid embolization (UFE) could exceed $200 million in the U.S. and $300 - $500 million worldwide. Embolic agents are also used in the treatment of inoperable liver cancer, a condition affecting approximately 75,000 people in the United States in 2005, with an annual market potential of $200 million U.S. and $400 million worldwide. About Protein Polymer Technologies, Inc. Protein Polymer Technologies, Inc. is a biotechnology company that discovers and develops innovative therapeutic devices to improve medical and surgical outcomes. The Company focuses on developing technology and products to be used for soft tissue augmentation, tissue adhesives and sealants, wound healing support and drug delivery devices. Protein Polymer Technologies' proprietary protein-based biomaterials are uniquely tailored to optimize clinical performance and contain no human or animal components that could potentially transmit or cause disease. The Company is headquartered in San Diego, California. For additional information about the Company, please visit www.ppti.com. To date, PPTI has been issued twenty-six U.S. patents on its core technology with corresponding issued and pending patents in key international markets. This press release contains forward-looking statements that are based on management's views and expectations. Actual results could differ materially from those expressed here; further, the Company is not obligated to comment specifically on those differences. Risks associated with the Company's activities include raising adequate capital to continue operations, scientific and product development uncertainties, competitive products and approaches, continuing collaborative partnership interest and funding, regulatory testing and approvals, and manufacturing scale up. The reader is encouraged to refer to the Company's 2004 Annual Report Form 10-KSB and 10KSB/A and other recent filings with the Securities and Exchange Commission, copies of which are available from the Company, to further ascertain the risks associated with the above statements. # # # Investor Contact: Media Contact: Erin Davis, (858) 558-6064 x 120 Bryan deCastro, (631) 495-9177 Protein Polymer Technologies, Inc. Carole Boucard, (954) 370-2524 Creative Public Relations -----END PRIVACY-ENHANCED MESSAGE-----